Mackenzie Financial Corp Increases Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Mackenzie Financial Corp lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 44.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 29,096 shares of the company's stock after acquiring an additional 8,977 shares during the period. Mackenzie Financial Corp's holdings in Hims & Hers Health were worth $704,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new position in Hims & Hers Health in the 4th quarter worth $28,000. Blume Capital Management Inc. raised its position in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the period. Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at about $38,000. Finally, US Bancorp DE increased its position in shares of Hims & Hers Health by 346.7% in the fourth quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after acquiring an additional 1,508 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Price Performance

NYSE:HIMS traded up $0.16 during mid-day trading on Thursday, hitting $53.77. 13,026,364 shares of the company's stock were exchanged, compared to its average volume of 20,414,346. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The business has a fifty day moving average price of $41.26 and a 200 day moving average price of $36.68. The company has a market cap of $12.04 billion, a PE ratio of 123.01 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health's quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.05 earnings per share. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, COO Melissa Baird sold 33,333 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the transaction, the chief operating officer now directly owns 805,083 shares of the company's stock, valued at $20,755,039.74. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the transaction, the chief executive officer now directly owns 173,655 shares of the company's stock, valued at $5,900,796.90. The trade was a 42.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 617,367 shares of company stock worth $25,227,888. Corporate insiders own 13.71% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HIMS. UBS Group restated a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Morgan Stanley decreased their price objective on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 29th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their price target for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Finally, Wall Street Zen upgraded shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.